Head and Neck Cancers Clinical Trial
Official title:
StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Patients Receiving Concurrent Chemoradiation for Head and Neck Cancers
Clinical significance and current evidence:
Radiation dermatitis occurs commonly in patients receiving chemoradiation for nasopharyngeal
cancer; 50 to 60% develop grade 2 or higher dermatitis. This can result in significant
morbidity, reduced aesthetic appearance, decrease in quality of life and delays in treatment.
Current literature does not conclusively support the use of one agent over another for
prevention of radiation dermatitis. The choice of agents used in clinical practice is highly
variable, with aqueous agents being one of the commonest.
Specific Aims:
The aim of this study is to evaluate if the investigational product (StrataXRT), a
silicone-based gel, is superior to standard clinical practice in prevention of grade 2 or
higher acute dermatitis in patients receiving chemoradiation for nasopharyngeal carcinoma.
Trial Design:
The study will be conducted using a prospective, double-blind randomized control trial in 2
institutions. Each arm will receive standard radiation to a total dose of 70 Gray (Gy) with
concurrent chemotherapy. The primary objective is to compare the prevention of dermatitis and
the primary endpoint is reached when grade 2 or higher dermatitis according to the Common
Terminology Criteria for Adverse Events (CTCAE) version 4.03 scale occurs. Secondary
objectives will be evaluation of the time to onset of dermatitis, the time to complete
recovery from dermatitis and the degree of pain. Assessment of the patient's skin will be
done at baseline, weekly during treatment, 1 week post treatment and unless the skin has
resolved to baseline then every week up until 6 weeks post-treatment, which will mark the end
of follow-up. The safety end-point is reached when grade 4 dermatitis occurs.
Hypothesis and statistics:
The investigators aim to demonstrate a 30% reduction in the incidence of grade 2 or higher
dermatitis with StrataXRT. Using a 2-sided test at significance level 0.05 to detect the
difference with a power of 80%, the investigators envisage a recruitment of 100-150 patients
in total. The study duration is estimated to be 2 years.
Status | Not yet recruiting |
Enrollment | 150 |
Est. completion date | August 2020 |
Est. primary completion date | June 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 80 Years |
Eligibility |
Inclusion Criteria: - patients who are 21 years of age or older - histological diagnosis of head and neck carcinoma available - patients who are to be treated with concurrent chemoradiation - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3 - no known allergy to StrataXRT or silicone - able to give written informed consent, or have written consent given on their behalf Exclusion Criteria: - patients who cannot apply the skin product or have it administered to them - patients with comorbidities and/or on medications that may alter the response of the skin e.g. connective tissue disorder - patients with existing rashes or wounds in the radiation field at baseline - patients receiving concurrent cetuximab during radiotherapy - previous radiotherapy to the head and neck region - female patients who are pregnant or breast feeding - unable to give written informed consent , or are unable to have written consent given on their behalf |
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University Hospital, Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | grade 2 acute radiation dermatitis | when patient develops grade 2 acute radiation dermatitis as scored by Common Terminology Criteria for Adverse Event (CTCAE) version 4.03 scale with grade 1 the mildest, Grade 1: faint erythema or dry desquamation Grade 2: moderate to brisk erythema; patchy moist desquamation; moderate edema Grade 3: moist desquamation other than skin folds and creases; bleeding induced by minor trauma or abrasion Grade 4: skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site Grade 5: death | 10 weeks | |
Secondary | completion of scheduled post-treatment assessment at 6 weeks post-radiotherapy | when patient completed the scheduled post-radiotherapy assessment | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00721539 -
Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract
|
N/A | |
Recruiting |
NCT00568490 -
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
|
||
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Completed |
NCT00313027 -
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
|
N/A | |
Completed |
NCT00186433 -
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
|
N/A | |
Recruiting |
NCT02997332 -
Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
Completed |
NCT02854358 -
Efficacy of Traditional Persian Medicine Preparation Versus Artificial Saliva for Radiation Induced Xerostomia
|
Phase 2 | |
Terminated |
NCT01114256 -
FNA Tumor Sampling for CD137 Modulation: A Pilot Study
|
N/A | |
Terminated |
NCT00965003 -
MRI Laryngeal Imaging With a Surface Coil
|
Early Phase 1 | |
Active, not recruiting |
NCT00490061 -
Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
|
Phase 2 | |
Recruiting |
NCT05122221 -
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
|
Phase 1 | |
Completed |
NCT02045368 -
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
|
Phase 1 | |
Completed |
NCT01908504 -
Adaptive Pet Study
|
N/A | |
Completed |
NCT05648682 -
Comparison of the Effectiveness of Three Different Gargates in Radiotherapy-Associated Oral Mucositis
|
N/A | |
Active, not recruiting |
NCT00580203 -
Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers
|
||
Completed |
NCT00230295 -
Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast
|
N/A | |
Completed |
NCT00610415 -
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study
|
N/A | |
Completed |
NCT01664936 -
Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes
|
||
Completed |
NCT01163487 -
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
|
Phase 1 | |
Terminated |
NCT01137162 -
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
|
N/A |